Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody
The DOI matches its Crossref record.
Abstract
The binding specificity of the murine OKT3 has been transferred into a human antibody framework to reduce its immunogenicity. This "humanized" anti-CD3 mAb (gOKT3-5) was previously shown to retain, in vitro, all the properties of native OKT3, including T cell activation, which has been correlated, in vivo, with the severe side effects observed in transplant recipients after the first administration of the mAb. T cell activation is thought to be triggered by the cross-linking mediated by the antibodies between T cells and Fc receptor-bearing cells. In this study, we introduced a single amino acid mutation from a leucine to a glutamic acid at position 235 in the Fc receptor binding segment of the gOKT3-5 mAb to produce Glu-235 mAb. This mutation generated a 100-fold decrease in the affinity of the antibody for the Fc receptor on U937 cells, without affecting Ag binding. In parallel, we observed a marked reduction in the T cell activation triggered by the mAb (proliferation, cell surface expression of early activation markers including Leu 23 and IL-2R, and release of TNF-alpha, IFN-gamma, and granulocyte macrophage-CSF). In contrast, the mutated mAb retained suppressive properties similar to the gOKT3-5 mAb, as assessed by significant modulation of the T cell receptor complex and suppression of Ag-specific CTL activity. We conclude that this anti-CD3 mAb bearing a single amino acid mutation in its Fc portion retains important immunosuppressive properties, while exhibiting significantly less T cell activation than OKT3 in vitro. This drug might achieve potent immunosuppression while minimizing acute toxicity in vivo and thus be useful in transplantation as well as in autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw040 · Cited by 425
Therapeutic monoclonal antibodies
Breedveld, F. (2000) · The Lancet · doi:10.1016/s0140-6736(00)01034-5 · Cited by 359
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
Type I IFNs Inhibit Human Dendritic Cell IL-12 Production and Th1 Cell Development
McRae, B. L., Semnani, R. T., Hayes, M. P., & van Seventer, G. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4298 · Cited by 260
Metadata
- Authors
- Alegre, M. L., Collins, A. M., Pulito, V. L., Brosius, R. A., Olson, W. C., Zivin, R. A., Knowles, R., Thistlethwaite, J. R., Jolliffe, L. K., & Bluestone, J. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1992-06-01
- Volume
- 148
- Issue
- 11
- Pages
- 3461-3468
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1483697311
- Cited by
- 115
- References
- 0
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. https://app.cochat.ai/papers/10.4049/jimmunol.148.11.3461
- The paper
- Alegre, M. L., Collins, A. M., Pulito, V. L., Brosius, R. A., Olson, W. C., Zivin, R. A., Knowles, R., Thistlethwaite, J. R., Jolliffe, L. K., & Bluestone, J. A. (1992). Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. The Journal of Immunology. https://doi.org/10.4049/jimmunol.148.11.3461
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.